摘要
目的 探讨血管内皮生长因子 (vascularendothelialgrowthfactor,VEGF)在肝硬化时的作用及血管紧张素Ⅱ受体拮抗剂Losartan对VEGF基因表达的影响。方法 大鼠肝硬化模型由CCl4诱导 ,41只雄性SD大鼠被随机分为 4组 :对照组 10、模型组 11、及治疗组 2 0 (早期 10、中期 10 ) ,除对照组外所有大鼠均给予 5 0 %CCl4灌胃 ,3ml·kg- 1 ·d- 1 ·次 - 1 ,共 9周。治疗组 :早期组同时血管紧张素受体拮抗剂灌胃 ,中期组于造模中期 (5周 )开始给药 ,用量 10mg·kg- 1 ·d- 1 至处死前。免疫组织化学及RT PCR检测VEGF蛋白、mRNA的表达。结果 肝硬化组VEGF蛋白、mRNA的表达由 0 77±0 10到 1 94± 0 2 0明显高于正常对照组 (P =0 0 0 1) ,而与肝硬化组相比Losartan治疗组VEGF表达明显降低到 1 0 2± 0 10及 0 86± 0 15 (P =0 0 0 1)。结论 肝硬化时VEGF表达增加 ,而Losartan可使其表达降低。
Objective To investigate the effect of L osartan, an angiotensin Ⅱ type receptor antagonist, on vascular endothelial gro wt h factor (VEGF) expression. Method Ｚ Liver cirrhosis was in duced by oral intake of 50% CCl4 at a dosage of 3?ml·kg-1·d- 1ⅹ 9 weeks in SD rats. In Losartan group,rats were given Losartan orally. Exp r ession of VEGFmRNA was examined with reverse transcriptase polymerase chain reac tion (RT-PCR) and the expression of VEprotein was assayed by immunohistochem istry. Result VEGF was highly e xpressed in cirrhotic group compared with control group (0.77±0.10 vs 1.94± 0.20, P=0.001) . In losartan treatment group, VEGF mRNA expression decreas ed to 1.02±0.1 and 0.86±0.15（P=0.001）. Concl usion Expression of VEGF increased in cirrhosis, Losartan inhibited this eff ect.
出处
《中华普通外科杂志》
CSCD
北大核心
2003年第2期112-113,共2页
Chinese Journal of General Surgery
